文献速递胸部肿瘤

早期肺癌机器人肺叶切除术后的生存结局简要报告

A Brief Report on Survival After Robotic Lobectomy for Early-Stage Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2019-08-19

该研究回顾性分析2011-2016年单中心1139例非小细胞肺癌肺叶切除术患者,主要比较544例早期临床N0患者(开放348例、机器人196例),并个体匹配131对。结果显示机器人组与开放组在无复发生存(HR 1.09,p=0.55)和总生存(HR 0.86,p=0.36)上均无差异,5年复发风险与总生存率分别为开放组24.9%和83.2%、机器人组24.6%和86.1%。结论认为机器人肺叶切除术治疗早期NSCLC安全可行,长期生存与开放手术相当。

要点

  • 机器人肺叶切除术与开放手术在早期NSCLC中无复发生存和总生存均无显著差异。
  • 匹配队列5年复发风险开放组24.9%、机器人组24.6%,总生存率分别为83.2%和86.1%。
  • 研究支持机器人肺叶切除术作为早期NSCLC安全可行的手术方式。

核心结论

  • 机器人辅助肺叶切除术治疗早期NSCLC安全可行,长期生存与开放手术相当。

研究设计与样本

  • 单中心回顾性内审研究,选取2011-2016年5年期间1139例接受肺叶切除术的NSCLC患者。
  • 主要分析544例早期临床N0患者,其中开放手术348例、机器人手术196例。
  • 进一步对每组131例患者进行个体匹配比较,人口学和临床特征几乎一致。

主要发现

  • 匹配队列中无复发生存无差异(HR 1.09,p=0.55)。
  • 匹配队列中总生存无差异(HR 0.86,p=0.36)。
  • 开放组5年复发风险和总生存率分别为24.9%和83.2%。
  • 机器人组5年复发风险和总生存率分别为24.6%和86.1%。

临床怎么用

  • 对于早期临床N0的NSCLC患者,机器人肺叶切除术可作为开放手术的可行替代选择。
  • 在充分评估手术条件后,机器人入路不影响长期肿瘤学生存结局。

局限性

  • 研究为单中心回顾性分析,可能存在选择偏倚。
  • 样本来自特定5年期间,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Robotic-assisted surgery has become the first choice for several conditions since its introduction in clinical practice in 2000. However, the U.S. Food and Drug Administration has recently raised a warning against the use of robotic surgical approaches for the cure and prevention of cancer following the publication of two studies focused on endometrial cancer. We conducted an internal audit to retrospectively analyze our experience to assess the safety and feasibility of robotic-assisted surgery compared to open surgery. METHODS: We selected a 5-year period to guarantee at least 2 years of follow-up (2011-2016) and identified 1139 patients who underwent lobectomy for NSCLC in our division. The primary data set analyzed included 544 early-stage clinical N0 patients (348 open and 196 robotic surgeries). We compared 131 patients of each group individually matched, with demographic and clinical characteristics almost identical. RESULTS: No difference was observed between the cohorts, either in terms of recurrence-free survival (hazard ratio: 1.09; p = 0.55) or overall survival (hazard ratio: 0.86; p = 0.36). The 5-year recurrence of disease risk and overall survival were 24.9% and 83.2%, respectively, in the open group and 24.6% and 86.1%, respectively, in the robotic group. CONCLUSIONS: These data underline that robotic-assisted lobectomy for early NSCLC is a safe and feasible technique with adequate long-term and progression-free survival compared to open surgery.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Spaggiari L, Sedda G, Maisonneuve P, et al. A Brief Report on Survival After Robotic Lobectomy for Early-Stage Lung Cancer. J Thorac Oncol. 2019. PMID: 31437532. doi:10.1016/j.jtho.2019.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。